Disclosed is the use of a compound of formula I, where the substituents are as defined herein, for example 4-(4-(cyclopentyloxy)-5-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-2-ylamino)-N-methylbenzamide and 4-(4-(cyclopropylamino)-5-(1-methyl-1H-pyrazol-4-yl)-7Hpyrrolo[2,3-d]pyrimidin-2-ylamino)-3-methoxy-N-methylbenzamide in the manufacture of a medicament for the treatment of cancer, especially solid tumours and haematological cancers such as colon cancer, lung cancer, bladder cancer, leukemia, lymphoma or multiple myeloma.
